Literature DB >> 23260083

Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer.

Jennifer L Dembinski1, Shanna M Wilson, Erika L Spaeth, Matus Studeny, Claudia Zompetta, Ismael Samudio, Katherine Roby, Michael Andreeff, Frank C Marini.   

Abstract

BACKGROUND AIMS: Many ovarian cancers originate from ovarian surface epithelium, where they develop from cysts intermixed with stroma. The stromal layer is critical to the progression and survival of the neoplasm and consequently is recruited into the tumor microenvironment.
METHODS: Using both syngeneic mouse tumors (ID8-R) and human xenograft (OVCAR3, SKOV3) tumor models, we first confirmed that intraperitoneally injected circulating mesenchymal stem cells (MSCs) could target, preferentially engraft and differentiate into α-smooth muscle actin-positive myofibroblasts, suggesting their role as "reactive stroma" in ovarian carcinoma development and confirming their potential as a targeted delivery vehicle for the intratumoral production of interferon-β (IFN-β). Mice with ovarian carcinomas then received weekly intraperitoneal injections of IFN-β expressing MSCs.
RESULTS: Intraperitoneal injections of IFN-β expressing MSCs resulted in complete eradication of tumors in 70% of treated OVCAR3 mice (P = 0.004) and an increased survival of treated SKOV3 mice compared with controls (P = 0.01). Similar tumor growth control was observed using murine IFN-β delivered by murine MSCs in ID8-R ovarian carcinoma. As a potential mechanism of tumor killing, MSCs produced IFN-β-induced caspase-dependent tumor cell apoptosis.
CONCLUSIONS: Our results demonstrate that ovarian carcinoma engrafts MSCs to participate in myofibrovascular networks and that IFN-β produced by MSCs intratumorally modulates tumor kinetics, resulting in prolonged survival. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23260083      PMCID: PMC3709838          DOI: 10.1016/j.jcyt.2012.10.003

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  41 in total

1.  Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines.

Authors:  M Chawla-Sarkar; D W Leaman; E C Borden
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

2.  Intraperitoneal administration of interferon beta in ovarian cancer patients.

Authors:  A Rambaldi; M Introna; F Colotta; S Landolfo; N Colombo; C Mangioni; A Mantovani
Journal:  Cancer       Date:  1985-07-15       Impact factor: 6.860

Review 3.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing.

Authors:  H F Dvorak
Journal:  N Engl J Med       Date:  1986-12-25       Impact factor: 91.245

4.  Pharmacokinetics, tissue distribution, and cell localization of [35S]methionine-labeled recombinant human and murine alpha interferons in mice.

Authors:  T G Johns; J A Kerry; B A Veitch; I R Mackay; P J Tutton; M J Tymms; B F Cheetham; P J Hertzog; A W Linnane
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

5.  Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

Authors:  Akinori Takaoka; Sumio Hayakawa; Hideyuki Yanai; Dagmar Stoiber; Hideo Negishi; Hideaki Kikuchi; Shigeru Sasaki; Kohzoh Imai; Tsukasa Shibue; Kenya Honda; Tadatsugu Taniguchi
Journal:  Nature       Date:  2003-07-31       Impact factor: 49.962

6.  Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.

Authors:  Matus Studeny; Frank C Marini; Richard E Champlin; Claudia Zompetta; Isaiah J Fidler; Michael Andreeff
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

Review 7.  Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis.

Authors:  M Chawla-Sarkar; D J Lindner; Y-F Liu; B R Williams; G C Sen; R H Silverman; E C Borden
Journal:  Apoptosis       Date:  2003-06       Impact factor: 4.677

8.  Growth-inhibitory activity of interferon-beta against human colorectal carcinoma cell lines.

Authors:  V L Wong; D J Rieman; L Aronson; B J Dalton; R Greig; M A Anzano
Journal:  Int J Cancer       Date:  1989-03-15       Impact factor: 7.396

9.  Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma.

Authors:  Adam M Sonabend; Ilya V Ulasov; Matthew A Tyler; Angel A Rivera; James M Mathis; Maciej S Lesniak
Journal:  Stem Cells       Date:  2008-01-10       Impact factor: 6.277

Review 10.  Interferons in the treatment of malignancies.

Authors:  D Kardamakis
Journal:  In Vivo       Date:  1991 Nov-Dec       Impact factor: 2.155

View more
  31 in total

Review 1.  Mesenchymal stem cells as delivery vectors for anti-tumor therapy.

Authors:  Zhenzhen Li; Dongmei Fan; Dongsheng Xiong
Journal:  Stem Cell Investig       Date:  2015-03-26

Review 2.  Engineering Stem Cells for Biomedical Applications.

Authors:  Perry T Yin; Edward Han; Ki-Bum Lee
Journal:  Adv Healthc Mater       Date:  2015-03-13       Impact factor: 9.933

Review 3.  The evolving relationship of wound healing and tumor stroma.

Authors:  Deshka S Foster; R Ellen Jones; Ryan C Ransom; Michael T Longaker; Jeffrey A Norton
Journal:  JCI Insight       Date:  2018-09-20

Review 4.  Mesenchymal stem cells: immune evasive, not immune privileged.

Authors:  James A Ankrum; Joon Faii Ong; Jeffrey M Karp
Journal:  Nat Biotechnol       Date:  2014-02-23       Impact factor: 54.908

5.  A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progression.

Authors:  Sabino Ciavarella; Anna Caselli; Antonella Valentina Tamma; Annalisa Savonarola; Giuseppe Loverro; Roberto Paganelli; Marco Tucci; Franco Silvestris
Journal:  Stem Cells Dev       Date:  2015-03-11       Impact factor: 3.272

6.  Conditioned Medium From Azurin-Expressing Human Mesenchymal Stromal Cells Demonstrates Antitumor Activity Against Breast and Lung Cancer Cell Lines.

Authors:  Marília Silva; Gabriel Amaro Monteiro; Arsenio M Fialho; Nuno Bernardes; Cláudia Lobato da Silva
Journal:  Front Cell Dev Biol       Date:  2020-07-09

Review 7.  Stem cell-based therapies for cancer treatment: separating hope from hype.

Authors:  Daniel W Stuckey; Khalid Shah
Journal:  Nat Rev Cancer       Date:  2014-09-01       Impact factor: 60.716

8.  Bioengineered adipose-derived stem cells for targeted enzyme-prodrug therapy of ovarian cancer intraperitoneal metastasis.

Authors:  Obeid M Malekshah; Siddik Sarkar; Alireza Nomani; Niket Patel; Parisa Javidian; Michael Goedken; Marianne Polunas; Pedro Louro; Arash Hatefi
Journal:  J Control Release       Date:  2019-09-06       Impact factor: 9.776

Review 9.  Stem cell-based therapies for tumors in the brain: are we there yet?

Authors:  Khalid Shah
Journal:  Neuro Oncol       Date:  2016-06-09       Impact factor: 12.300

Review 10.  Interplay between mesenchymal stem cell and tumor and potential application.

Authors:  Qing Wang; Ti Li; Wei Wu; Gang Ding
Journal:  Hum Cell       Date:  2020-05-06       Impact factor: 4.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.